Longevity Biotech Social
2025-08-01 19:00 - 22:00 UTC | Oxford Blue, 32 Marston St, Oxford, United Kingdom, OX4 1JU
Join us for an informal evening bringing together scientists, entrepreneurs, investors, students, and anyone curious about the future of healthy aging and biotechnology.
​This is a casual networking event — no formal presentations, just real conversations, idea-sharing, and meeting like-minded people who care about longevity science and innovation.
​✅ Drinks: Drinks (including non-alcoholic options) are available for purchase at the venue — please note drinks are not included in the ticket. Everyone orders and pays individually at the bar.
✅ Age policy: Open to attendees aged 18+; please bring valid ID if you wish to buy alcohol.
✅ Accessibility: The venue is wheelchair accessible.
✅ All are welcome: Whether you work in biotech, are studying, investing, or simply curious about the science of living longer — you belong here.
✅ Community vibe: Come ready to chat, ask questions, and share your passion. Even if attendance is small, we’ll keep it friendly and meaningful.
​Come network, collaborate, and be part of the movement to shape the future of longevity.

VC Insights on the Future of Longevity Biotech
2025-08-22 20:00 - 21:30
Join us for an exclusive session with Sebastian Brunemeier, one of the most influential figures at the intersection of biotechnology, ageing research, and venture capital.
​Sebastian A. Brunemeier is a biotech VC and company builder focused on longevity & regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital, and Partner at Long Game Ventures. Previously, he was Principal at Apollo Health Ventures, the largest longevity fund in the world, CIO and Co-Founder at Cambrian Biopharma, and Founder of Samsara Therapeutics. He was a DPhil (PhD) Clarendon Scholar in Biochemistry at the University of Oxford, a Fulbright Fellow, a Skaggs-Oxford Scholar at the Scripps Research Institute, and holds a dual MSc in Molecular Neuroscience and Biotech Business Management from University of Amsterdam.
​In this session, Sebastian will share insights on:

​The global longevity biotech investment landscape
​What makes a longevity startup investor-ready
​The intersection of science, entrepreneurship, and capital
​Career pathways for students and researchers in the field
​His own journey from academic ageing research to founding and funding frontier biotech ventures

​Open to all students, faculty, researchers, and future founders interested in biotech, aging science, and healthspan innovation.
​Event Highlights:

​Deep dive into the world of longevity investing and emerging biotech
​Learn what makes a longevity startup investor-ready
​Breathtaking view of London from the 32nd floor venue
​Complimentary Longevity Protein Shake Samples to fuel your healthspan journey

Rehydration OSAL's Welcome Social
2026-02-04 19:00 | Jesus College Bar, Turl Street, Oxford, OX1 3DW
Join us for our first social of the year to get to know members of the society and what other events we have in store this term!

Genflow Biosciences: Translating longevity research to the bedside
2026-02-16 18:00 | David Smith Lecture Theatre Department of Pharmacology Mansfield Road Oxford OX1 3QT United Kingdom, David Smith Lecture Theatre Department of Pharmacology Mansfield Road, Oxford United Kingdom, OX1 3QT, United Kingdom
Dr. Eric Leire is the Founder and CEO of Genflow Biosciences, a longevity gene therapy company listed on the London Stock Exchange. An MD and MBA (HEC/Kellogg), he combines research experience from the Harvard AIDS Institute with executive leadership at Pfizer and Biofund Venture Capital. Dr. Leire has guided multiple biotech companies to public listings (Nasdaq) and holds several pharmaceutical patents.

Early detection for dementia, an oxymoron? Examining the evidence from population studies
2026-03-10 18:00 | David Smith Lecture Theatre, Department of Pharmacology, Mansfield Road, Oxford OX1 3QT, David Smith Lecture Theatre, Department of Pharmacology, Mansfield Road,, Oxford, OX1 3QT
We’re delighted to invite you to an in‑person OSAL event with Professor Carol Brayne, one of the leading public health voices in dementia and ageing.
Early detection for dementia is often treated as an obvious good: find it earlier, fix it earlier. In this talk, Professor Brayne will challenge that simple narrative, drawing on decades of population‑based research to ask when dementia really becomes detectable, what “early” labels actually tell us about the future, and how screening can both help and harm.
She will explore:

How dementia trends have changed over time in real‑world populations
Why mild memory problems and “preclinical” labels do not always progress to dementia
The gap between tests/biomarkers and people’s lived cognitive function
The ethical and practical dilemmas of telling people they are “at risk” years before symptoms may—or may not—develop

What do epigenetic clocks teach us about ageing and longevity?
2026-03-17 18:00 | Rhodes Trust Lecture Theatre, Oxford, OX11HP
We’re delighted to invite you to an in‑person event with Professor Steve Horvath, one of the world’s most influential ageing researchers and a principal investigator at Altos Labs. This event is co-hosted by the Oxford Society of Ageing and Longevity(OSAL) and the Consumer, Media and Lifestyle OBN at Saïd Business School.
The development of DNA methylation-based epigenetic clocks has revolutionized our ability to measure biological age across tissues and species. In this talk, Professor Horvath will synthesize insights from his foundational clocks, such as PhenoAge and GrimAge, to discuss what they reveal about individual ageing trajectories and how lifestyle, environment, and chronic disease accelerate biological ageing. He will also rigorously address the promise and limitations of these tools as surrogate endpoints in translational geroscience and anti-ageing clinical trials.

Taking Rejuvenation to Longevity Escape Velocity: Aubrey de Grey
2026-05-18 18:30 - 19:30
We are delighted to host Dr Aubrey de Grey, President and Chief Science Officer of the Longevity Escape Velocity (LEV) Foundation, for a live online talk with the Oxford Society of Ageing and Longevity. Dr de Grey is a biomedical gerontologist best known for pioneering the idea that ageing is a medically tractable condition and for his work on the SENS framework, which targets the cellular and molecular damage that accumulates with age.
​In this talk, “Taking Rejuvenation to Longevity Escape Velocity”, Dr de Grey will outline the scientific rationale and current progress toward therapies that may not only slow but potentially reverse aspects of biological ageing. He will discuss the concept of longevity escape velocity—the point at which advances in rejuvenation biotechnology extend healthy lifespan faster than time passes—and examine what scientific, technological, and translational milestones are needed to reach it. Drawing on his decades of work in biogerontology and advocacy for damage‑repair approaches, he will also reflect on the opportunities and bottlenecks facing the longevity field today.
​The event will be held online via Zoom at 6:30pm UK time, featuring a 30‑minute presentation followed by an extended audience Q&A. The Oxford Society of Ageing and Longevity is a student‑led organisation highlighting cutting‑edge ageing research and rejuvenation biotechnology; this event is open to students, researchers, clinicians, and anyone interested in the future of ageing science, longevity biotechnology, and the prospect of bringing ageing under medical control.

Jonathan Wolf - ZOE: The reality of Health and AI in 2026
2026-06-10 17:00 - 18:30 | Jesus College Oxford, Jesus College, Turl St, Oxford, OX1 3DW, United Kingdom
​Oxford Society for Ageing and Longevity is delighted to welcome Jonathan Wolf, co-founder and CEO of ZOE. Drawing on experience from building the world’s largest nutrition science study, Jonathan will share what cutting-edge research is revealing about food, gut health, and AI, and explore what these insights could mean for the future of healthcare innovation.
​​Jonathan Wolf is the co-founder and CEO of ZOE, a gut health science company that turns world-leading science into everyday gut-health products.
​ZOE is famous for three products: its gut health supplement Daily30, the ZOE app, and its podcast, ZOE Science + Nutrition, which is the world’s #1 nutrition podcast.
​ZOE also runs the world’s largest gut health science study, publishing breakthrough research in some of the world’s most influential journals, from The Lancet to Nature.
​Before launching ZOE, Jonathan was Chief Product Officer at Criteo, helping the company grow from a 30-person startup to a NASDAQ-listed business with over $1B in revenue. Earlier in his career, he worked at Yahoo.
​Jonathan studied Physics at Oxford, where he received the Gibbs Prize and served as President of the Oxford Union. He later studied at Harvard and is a Foundation Fellow at Corpus Christi College, Oxford.
